MONTREAL, April 28,
2022 /CNW/ - Valeo Pharma Inc. (TSX:VPH) (OTCQB:
VPHIF) (FSE:VP2) ("Valeo" or the "Company"), a
Canadian pharmaceutical company, today announces the results of the
proposals submitted to shareholders at its annual meeting of
shareholders held on April 27, 2022
(the "Meeting").
Proposal No. 1: Election of Directors
The results of the vote for those elected as directors are as
follows:
Nominee
|
|
Votes
For
|
|
Votes
Withheld
|
|
|
Number
|
|
%
|
|
Numbers
|
|
%
|
Steve Saviuk
|
|
9,538,719
|
|
96.80
|
|
315,185
|
|
3.20
|
Richard
MacKay
|
|
9,517,719
|
|
96.59
|
|
336,185
|
|
3.41
|
Vincent
Hogue
|
|
9,849,194
|
|
99.95
|
|
4,710
|
|
0.05
|
Maureen
Brennan
|
|
9,849,219
|
|
99.95
|
|
4,685
|
|
0.05
|
Michel
Trudeau
|
|
9,851,794
|
|
99.98
|
|
2,110
|
|
0.02
|
Frederic
Fasano
|
|
9,541,404
|
|
96.83
|
|
312,500
|
|
3.17
|
Proposal No. 2: Apppointment of the
auditor
The results of the vote for the appointment of
PricewaterhouseCoopers LLP as the independent registered
public accounting firm for Valeo are as follows:
Votes
For
|
|
Votes
Withheld
|
Number
|
|
%
|
|
Numbers
|
|
%
|
9,970,578
|
|
100
|
|
25
|
|
0.00
|
Appointments
Following the Meeting, the following appointments were made and
committees confirmed by the newly elected board of directors of
Valeo (the "Board"):
Board Chairman: Richard
D. MacKay
Audit Committee Chairman: Michel Trudeau
Audit Committee Members: Frederic Fasano and Vincent P. Hogue
Corporate Governance and Human Resources Committee
Chairman: Vincent P.
Hogue
Corporate Governance and Human Resources Committee
Members: Maureen C. Brennan
and Steve Saviuk
In addition, the Board is pleased to announce the appointment of
Marc Léger as director of the Company.
"I am pleased to welcome Marc to our Board of Directors. Marc
had a long career as a senior executive in the Canadian
pharmaceutical industry including 12 years with Valeo, the last 3
as Senior Vice-President and Chief Commercial Officer", said
Steve Saviuk, Valeo's Chief
Executive Officer. "We look forward to benefiting from his
strategic insight and guidance as Valeo continues to pursue its
ambitious growth objectives".
More about Mr. Marc Léger
Mr. Léger is a seasoned pharmaceutical executive with
pan-Canadian and U.S. experience in both the prescription
pharmaceutical and consumer healthcare businesses. He has extensive
experience in building and leading organizations and has an
excellent track record of developing best in class brands.
Mr. Léger began his career in the pharmaceutical industry in
1984 with Schering Canada as a sales representative in British Columbia. He progressed through the
organization in a variety of roles in the marketing and sales
departments (Canada and U.S.)
leading to the role of Vice President, Primary Care Business Unit
(1997-2002) and subsequently to the role of General Manager,
Schering-Plough Healthcare Canada (2002-2008), where he led the
Consumer Health Business. During his career at Schering-Plough, Mr.
Léger was directly involved with the launch and/or development of
over 20 brands which became leading brands in their respective
markets, and managed and led several organizational structure
changes. Mr. Leger has previously served on the Board of
Schering Canada Inc.
In February 2009, Mr. Léger joined
Valeo Pharma, leading the Commercial Operations where he was
directly involved with the development of both the dermatology and
specialty products businesses, which were in part sold to Valeant
Pharmaceuticals Inc. (now Bausch Health) in 2014. Prior to his
retirement from Valeo in 2021, Mr. Léger was acting as Senior VP
and Chief Commercial Officer for Valeo..
Mr. Léger graduated from Concordia
University (Montreal, Qc) in 1984 with a Bachelor of Arts
degree (Economics).
Grants under the Incentive Compensation Plan
The Company also announces that it granted an aggregate of
175,926 restricted share units ("RSUs"), vesting one year
from grant and 387,500 stock options ("Options") to certain
officers, directors and management team members of the Company in
accordance with the Company's incentive compensation plan.
The Options will be exercisable at an exercise price of
$0.66 per Class A common share of the
Company until April 27, 2027, and will vest annually from 1 to
3 years.
About Valeo Pharma
Valeo Pharma is a pharmaceutical company dedicated to the
commercialization of innovative prescription products in
Canada with a focus on
Respirology, Neurodegenerative Diseases, Oncology and other
specialty products. Headquartered in Kirkland, Quebec, Valeo Pharma has the full
capability and complete infrastructure to register and properly
manage its growing product portfolio through all stages of
commercialization. For more information, please visit
www.valeopharma.com and follow us on LinkedIn and Twitter.
Forward Looking Statements
This press release contains forward-looking statements about
Valeo's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate.
SOURCE Valeo Pharma Inc.